Journal article

T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review

Jessica WY Wu, Sudiksha Dand, Lachlan Doig, Anthony T Papenfuss, Clare L Scott, Gwo Ho, Joshua D Ooi



Ovarian cancer, in particularly high-grade serous ovarian cancer (HGSOC) and ovarian carcinosarcoma (OCS), are highly aggressive and deadly female cancers with limited treatment options. These tumors are generally unresponsive to immune check-point inhibitor (ICI) therapy and are referred to as immunologically "cold" tumors. Cell-based therapy, in particular, adoptive T-cell therapy, is an alternative immunotherapy option that has shown great potential, especially chimeric antigen receptor T cell (CAR-T) therapy in the treatment of hematologic malignancies. However, the efficacy of CAR-T therapy in solid tumors has been modest. This review explores the potential of another cell-based therapy..

View full abstract


Awarded by Victorian Cancer Agency

Funding Acknowledgements

GH is funded by a School of Clinical Sciences, Monash University Clinician-Scientist Early Career Fellowship. JO is an Al and Val Rosenstrauss Fellow funded by the Rebecca Cooper Medical Foundation. Clare Scott is funded by the Stafford Fox Medical Research Foundation (CLS); Cancer Council Victoria (Sir Edward Dunlop Fellowship in Cancer Research to CLS); the Victorian Cancer Agency (Clinical Fellowships to CLS CRF1020, CRF16014.